SCHEMBL7010837

SCHEMBL7010837

c1ccc(-c2cc(C3OCCO3)cs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.46
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
MEN1 O00255 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B1 P14061 3/20 0.35
HSD17B2 P37059 3/20 0.35
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
CHRNA7 P36544 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
CNR1 P21554 1/20 0.33
DYRK1A Q13627 1/20 0.32
DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28293807 0.77 AR (0.42) ARGABRA1GABRG2GABRB3HSD17B1
Biphenyl SCHEMBL28725381 0.73 MEN1 (0.56) MEN1CYP2C19KMT2ATSHR
SCHEMBL3597677 0.71 MEN1 (0.48) MEN1CYP2C19KMT2ACYP2C9TSHR
SCHEMBL27614692 0.70 SLC6A4 (0.42) CYP3A4CYP2C9PRKDCCYP2E1CYP2A6
SCHEMBL366283 0.70 CYP2C19 (0.62) MEN1CYP2C19KMT2ATSHR
SCHEMBL30358225 0.69 CCNB2 (0.44) MEN1CYP2C19KMT2ACCNB2CDK1
SCHEMBL7010771 0.68
SCHEMBL12320830 0.68 RAB9A (0.33)
SCHEMBL11205547 0.67 AR (0.43) ARMEN1CYP2C19KMT2AHSD17B1
SCHEMBL23554913 0.67 SMN1; SMN2 (0.51) MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0690863-B1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LAB (US) 2003-03-05 EP disclosed
US-5597832-A TREATMENT OF NEUROLOGICAL, PSYCHOLOGICAL, CARDIOVASCULAR DISORDERS, AND SUBSTANCE ABUSE, BEHAVIOR DISORDERS, COGNITIVE IMPAIRMENT AND ATTENTION DEFICIT DISORDER ABBOTT LABORATORIES (US) 1997-01-28 US disclosed
EP-0690863-A1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1996-01-10 EP disclosed
EP-0690863-A4 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LAB (US) 1995-11-07 EP disclosed
WO-1994022858-A1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1994-10-13 WO disclosed
EP-0032432-B1 PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS GLAXO GROUP LIMITED (GB) 1985-07-24 EP disclosed
US-4438111-A PROSTAGLANDINS, ANTICOAGULANTS, ANTIASTHMA GLAXO GROUP LIMITED (GB) 1984-03-20 US disclosed
US-4371530-A INTIOCOAGULANTS, BRONCHODILATORS GLAXO GROUP LIMITED (GB) 1983-02-01 US disclosed
US-4327092-A USEFUL AS ANTICOAGULANTS AND ANTI-HISTAMINES GLAXO GROUP LIMITED (GB) 1982-04-27 US disclosed
EP-0032432-A1 Prostanoid compounds and their preparation and pharmaceutical formulations GLAXO GROUP LIMITED (GB) 1981-07-22 EP disclosed